Brought to you by 
Roche signs on for rights to Plexxikon's PLX4032 cancer agent
22 Nov 2022
Executive Summary
Plexxikon (uses Scaffold-Based Drug Discovery technology for structural screening and analysis of small molecules) has licensed Roche exclusive worldwide development and marketing rights to PLX4032 for cancer.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche signs on for rights to Plexxikon's PLX4032 cancer agent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice